Is Mar­tin Shkre­li blog­ging from prison?

Say what you will about Mar­tin Shkre­li, but the guy ap­pears to have a re­lent­less re­silience to be heard. A few months in­to his prison sen­tence at Fort Dix, Shkre­li might be blog­ging from his cell.

That’s ac­cord­ing to ac­tiv­i­ty on this site — mar­tin­shkre­ — which saw its first en­try post­ed yes­ter­day. Al­though it’s still un­clear if the blog is gen­uine, the first post was writ­ten in Shkre­li’s now-fa­mil­iar wry voice and style. He shares his per­son­al con­tact in­for­ma­tion, in­clud­ing an email ad­dress you can send ques­tions to. His peo­ple will print the emails and “snail mail” them to Shkre­li at the cor­rec­tion­al fa­cil­i­ty, the post says.

I’ve reached out to Fort Dix, the prison where Shkre­li is cur­rent­ly serv­ing his 7-year sen­tence for se­cu­ri­ties fraud, to see if Shkre­li can ac­tu­al­ly post blogs while in­car­cer­at­ed. What ac­cess does he have to the in­ter­net? In what cir­cum­stances would the fa­cil­i­ty in­ter­fere with his blog­ging? The in­sti­tu­tion took my call, but said it need­ed time to re­spond. I’m still wait­ing to hear back.

If the blog is in­deed gen­uine, it seems Shkre­li is de­ter­mined to share his thoughts on in­dus­try mat­ters. The first sec­tion of his first en­try is com­men­tary on bio stocks and in­dus­try news, with mus­ings like the one be­low:

No­var­tis’ much-telegraphed sale of Al­con and the con­tin­ued im­plo­sion of GE re­minds us con­glom­er­ates are more out of fash­ion than prob­a­bly at any point in the his­to­ry of busi­ness. This flies in the face of me­chan­i­cal log­ic, but prac­ti­cal­ly makes sense. Find­ing good man­agers is hard (I’ve maybe found a very small hand­ful of de­cent man­agers out of close to 1000 I’ve em­ployed over the years) and con­glom­er­ates can on­ly work if you have an en­gaged CEO (about 5% of CEOs) and en­gaged man­agers (less than 5%? less than 10%?), which prob­a­bil­i­ty tells you is far low­er.

Then he out­lines sci­en­tif­ic pa­pers he’s read from prison and adds notes on what he thinks about each. Last, he ded­i­cates a few para­graphs to his per­son­al life.

“I have around 38 months to go as­sum­ing no suc­cess on an ap­peal,” he wrote. “I spend most of my team [sic] read­ing. A news­pa­per mis­re­port­ed that I’m ‘buff’. This is not the case.”

He al­so writes that news out­lets have mis­re­port­ed facts about his as­sets.

“Oh, the Wu-Tang al­bum is still in my pos­ses­sion,” he wrote. “As are all of my as­sets.”

News writ­ers re­port­ed back in March that US Dis­trict Judge Kiyo Mat­sumo­to or­dered Shkre­li to for­feit $7.36 mil­lion. But that or­der got stayed — as we re­port­ed — pend­ing Shkre­li’s ap­peal, which could take a year or so to wrap up.

The news of Shkre­li’s blog was first not­ed by Christie Smythe, a le­gal jour­nal­ist who’s writ­ing a book about Shkre­li. Fol­low the con­ver­sa­tion via this tweet, and we’ll up­date this sto­ry once Fort Dix gets back to us:

Im­age: Mar­tin Shkre­li. SHUT­TER­STOCK

UP­DAT­ED: Roche bags 'break­through' an­ti-fi­bro­sis drug in $1.4B biotech buy­out deal

Roche is snapping up a “breakthrough” anti-fibrotic drug in a $1.4 billion buyout.

The pharma giant announced Friday that it is acquiring Promedior, primarily to get its hands on PRM-151, a recombinant form of human pentraxin-2 (PTX-2) protein that has nailed down mid-stage clinical data on idiopathic pulmonary fibrosis and demonstrating its potential for a range of fibrotic conditions.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,600+ biopharma pros reading Endpoints daily — and it's free.

(Image: Associated Press)

Amarin emerges from an ex­pert pan­el re­view with a clear en­dorse­ment for Vas­cepa and high odds of suc­cess when the FDA weighs in for­mal­ly

Several FDA experts who gathered Thursday to consider the landmark approval of Vascepa to reduce cardio events in an at-risk population voiced their unease about various aspects of the efficacy and safety data, or ultimately the population it should be used to treat. But the overwhelming belief that the data pointed to the drug’s benefit and clearly outweighed risks carried the day for Amarin.

The panel voted unanimously (16 to 0) to support the company’s positive data presentation — backing an OK for expanding the label to include reducing cardio risk. The vote points Amarin $AMRN down a short path to a formal decision by the FDA, with the odds heavily in its favor. Chances are the rest of the questions about the future of this drug will be hashed out in the label’s small print.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,600+ biopharma pros reading Endpoints daily — and it's free.

No­var­tis spin­out’s first an­ti-ag­ing PhI­II is a flop, so now they’ll turn to Parkin­son’s chal­lenge as shares wilt

Novartis spinout resTORbio is grappling with the collapse of its lead clinical program this morning — an anti-aging R&D failure that will badly damage their rep in the field.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,600+ biopharma pros reading Endpoints daily — and it's free.

(Image: Associated Press)

No­var­tis scores its lat­est FDA OK — this time for a new sick­le cell dis­ease drug picked up in a $665M deal

Novartis’ decision to buy Oklahoma-based biotech Selexys 3 years ago for up to $665 million has paid off with an FDA approval today.

Blessed with the FDA’s breakthrough drug designation for a speedy review, the pharma giant has pinned down an approval for crizanlizumab, a new therapy designed to reduce the frequency of painful incidents of vaso-occlusive crises among sickle cell disease patients 16 or older.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,600+ biopharma pros reading Endpoints daily — and it's free.

As­traZeneca gains EU nod for di­a­betes triple; Am­gen and Duke launch re­al-world PC­SK9 ob­ser­va­tion­al study

→ Weeks after winning EU approval to start marketing dapagliflozin as Forxiga, AstraZeneca has racked up another OK for a triplet combo involving the SGLT2 diabetes drug. Named Qtrilmet, the pill combines Forxiga with the DPP-4 inhibitor Onglyza (saxagliptin) and the bedrock drug metformin in a modified-release format. That 3-in-1 approach proved superior in reducing average blood glucose levels to a number of other dual combinations across 5 Phase III trials, including Forxiga plus metformin, Onglyza with metformin, or glimepiride with metformin.

Five drugs, in­clud­ing two No­var­tis ther­a­pies, win EMA en­dorse­ment

As is custom, an EMA panel on Friday issued its weekly recommendations on marketing applications submitted by drug developers. This week, the agency backed the use of five new therapies — including two Novartis drugs — but issued no negative reviews.

Novartis’ S1P drug for relapsing forms of multiple sclerosis (MS) drug, Mayzent (known chemically as siponimod), which was approved by the FDA in March — has been given the nod by the EMA. The Swiss drugmaker already sells its other MS drug, Gilenya, in both regions.

Atom­wise's X-37 spin­out gets $14.5 mil­lion to launch AI dis­cov­ery ef­forts

The folks behind Atomwise’s spinout X-37 like to think in cosmological metaphors, and you can think of their AI drug development model as probes sent into space from a central station. That station just got $14.5 million in Series A funding from DCVC Bio, Alpha Intelligence Capital and Hemi Ventures to back those missions.

X-37 uses Atomwise’s AI platform to identify drug targets and – unlike the parent company, which largely sticks to computers  – bring those into a wet lab and preclinical testing.  In addition to AI professionals, it’s led in by part by drug developers from Velocity Pharmaceutical Development.

Ab­bott Lab­o­ra­to­ries CEO Miles White pass­es ba­ton down to suc­ces­sor; Lon­za CEO Marc Funk hits the ex­it

→ Abbott Laboratories has named a successor to CEO Miles White after he announced that he was stepping down in March after 21 years of service. Robert Ford, the company’s COO and president, will take the helm. Ford is known for his work in the $25 billion merger between St. Jude Medical into Abbott in January 2017. White will remain with the company as executive chairman of the board. 

→ After snapping up Novartis’ Swiss facility, Novartis Center of Excellence, in July, Lonza has announced that their CEO, Marc Funk, is hitting the exit for “personal reasons.” Funk has been the CEO of the company for less than a year — brought onto the company back in March. In the meantime, chairman Albert Baehny will serve as interim CEO. 

UCB adds on more pos­i­tive PhI­II da­ta for IL-17A/17F in­hibitor bimek­izum­ab, clear­ing a path to the FDA

A month after posting positive top-line data from their first Phase III trial of the IL-17A/17F inhibitor bimekizumab, Belgium’s UCB says they’ve added more upbeat results from their second late-stage test in moderate-to-severe plaque psoriasis.

That leaves the company on track for regulatory submissions in the middle of next year, says CMO Iris Loew-Friedrich.
Their drug beat out a placebo on the co-primaries — a 90% improvement in PASI 90 (the Psoriasis Area and Severity Index) and Investigator Global Assessment (IGA) response of clear or almost clear (IGA 0/1) at week 16, compared to placebo. Investigators also boasted of hitting some key secondaries.
UCB is angling to enter an increasingly crowded market space.
In their first of 3 Phase III studies for bimekizumab, researchers touted top-line wins on statistically significant results on clearing plaque psoriasis, including a victory over J&J’s IL-23 contender Stelara on key endpoints. The drug targets both IL-17A and IL-17F, a modification on the IL-17A strategy laid out for Taltz (Eli Lilly) and Cosentyx (Novartis). And the new group also includes J&J’s Tremfya and AbbVie’s Skyrizi.

Social image: UCB